Medtronic Introduces MiniMed™ Mio™ Advance Infusion Set Enabling Fewer Insertion Steps for People with Diabetes in the U.S.

Medtronic plc today introduced the MiniMed™ Mio™ Advance infusion set to all Medtronic insulin pump customers in the United States. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed™ portfolio of infusion sets and gives people using insulin pumps an optimal user experience with fewer steps1.

The MiniMed Mio Advance infusion set is inserted in only four steps — individuals simply peel, pinch, place, and press to insert the infusion set.

The user-friendly design of the MiniMed Mio Advance infusion set enables:

  • One-handed insertion and flexibility to access more insertion sites1 on the body such as the lower back or back of the arm.
  • A fully hidden needle before, during, and after insertion.
  • Consistent insertion force with the built-in insertion device (called a “serter”).
  • Fewer insertion steps.
  • Rotation of sites for better skin health and insulin absorption1.

“Early feedback on the MiniMed Mio Advance infusion set has been fantastic,” said Krista Sugerman, vice president and general manager, Customer Retention and Experience for the Diabetes Group at Medtronic. “Our goal is to continuously improve and innovate core technologies to help people with diabetes continue to experience greater freedom and better health. We are excited to now make this infusion set available to more people and make the daily management of diabetes easier for our customers.”

Feedback from Medtronic Ambassadors using the MiniMed Mio Advance infusion set has been overwhelmingly positive:

“It was very easy to remove off of her body and it was not painful.” – Carlos, father of 13-year-old Medtronic insulin pump user

”The Mio Advance is easy to insert and pain free throughout the duration, I really like not having to carry a separate inserter.” – Mark, Medtronic insulin pump user

The MiniMed Mio Advance infusion set launched in select countries outside the U.S. in 2018 with 85% of patients preferring it to previous infusion sets2. MiniMed Mio Advance is manufactured by ConvaTec’s Unomedical subsidiary and is only available from Medtronic.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version